Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.


IDSA Resources: Pharmacology

SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Infectious Diseases Society of America (IDSA) COVID-19 Real-Time Learning Network. These resources are categorized as Pharmacology

Vaccine Development
The vaccine landscape for COVID-19 is rapidly evolving. This page an overview of publicly available information regarding current vaccine trials.
 
Therapeutics Under Current Investigation
There are many therapeutics under early investigation for treatment of COVID-19 for which there is currently insufficient clinical data to recommend either for or against. This overview is not a comprehensive summary, but a list of therapeutics with strong biological plausibility that are available in the United States and are or will be studied by clinical trial.
 
Monoclonal Antibodies
Information regarding monoclonal antibodies, a therapeutic agent under investigation for the treatment of COVID-19.

COVID-19 Podcast: The Latest on Monoclonal Antibodies (Dec. 19, 2020)
While monoclonal antibody treatments have performed well in the fight against COVID-19, administering the drugs can be time-consuming and costly.

Moderna COVID-19 Vaccine
This is a link to the IDSA Real-Time Learning Network external resource regarding the Moderna COVID-19 vaccine.

ASCO/IDSA Webinar: The COVID-19 Vaccine & Patients with Cancer 
This is a link to the IDSA Real-Time Learning Network external resource regarding the COVID-19 Vaccine and patients with cancer.

Vaccines & Immunity 
As vaccine candidates for COVID-19 continue development, refer here for updates on research and trials. This collection includes preliminary information on distribution planning which will be updated as trials progress.

Convalescent Plasma
This is a link to the IDSA Real-Time Learning Network external resources regarding convalescent plasma therapy and COVID-19. 

Tocilizumab 
This is a link to the IDSA Real-Time Learning Network external resources regarding tocilizumab and COVID-19. 

Vaccine FAQs
This is a link to the IDSA Real-Time Learning Network external resources regarding COVID-19. This is a link to a page covering COVID-19 FAQs. 

IDSA Guidelines on the Treatment and Management of Patients with COVID-19
This is a link to the IDSA Real-Time Learning Network external resources regarding guidelines for treating and managing COVID-19 patients. 

Johnson & Johnson/JanssenCOVID-19 Vaccine
This is a link to the IDSA Real-Time Learning link covering the newly approved COVID-19 vaccine from Johnson & Johnson/Janssen.  

IDSA COVID-19 Real-Time Learning Network: COVID-19: Vaccine-induced Immune Thrombotic Thrombocytopenia (Podcast)
This is a link to the IDSA Real-Time Learning Network external resources regarding the  April 13, 2021, FDA and CDC recommendation to pause the use of the Johnson & Johnson/Janssen COVID-19 vaccine after cases of a rare form of blood clotting were reported. In this episode, produced in partnership with the American Society of Hematology, we explore the topic of vaccine-induced immune thrombotic thrombocytopenia with hematologists.

IDSA COVID-19 Real-Time Learning Network: Corticosteroids
This is a link to the IDSA Real-Time Learning Network external resources regarding the use of corticosteriods for treating COVID-19 infection.

Vaccine Education Roundtable: Reaching Vaccine Hesitant Populations, Part 1
Associate Editor Mati Hlatshwayo Davis, MD, MPH, discussed strategies for reaching vaccine hesitant patients with Raul Macias Gil, MD, Jasmine Marcelin, MD, FACP, FIDSA, and Beth Prusaczyk, PhD, MSW. In the first half of the roundtable, panelists discuss the challenges of addressing misinformation, reasons for historical mistrust among various populations and their experiences discussing vaccine concerns with patients.
 
Vaccine Education Roundtable: Reaching Vaccine Hesitant Populations, Part 2
Associate Editor Mati Hlatshwayo Davis, MD, MPH, discussed strategies for reaching vaccine hesitant patients with Raul Macias Gil, MD, Jasmine Marcelin, MD, FACP, FIDSA, and Beth Prusaczyk, PhD, MSW. In the final half of the roundtable, panelists share strategies for discussing vaccine concerns and the crucial role that engaging trusted messengers in local communities has in providing reliable information to build vaccine confidence.   
 
Additional Dose Administration in Certain Immunocompromised Populations
This IDSA RTNL update details COVID-19 vaccine administration for immunocompromised patients.
 
Immunomodulators
This resource details the use of immunomodulators to treat COVID-19.


The information provided is for educational purposes for SCCM members and the general public. Clicking on these links allows users to leave www.sccm.org. The Society does not control the linked sites or the content on those sites. SCCM does not assume any liability for the content or information contained on these linked sites. Further, SCCM does not assume any liability or warrant with respect to the quality, noninfringement, accuracy, completeness, timeliness, or reliability of such linked sites.You should be aware that other internet sites that link to the Site may contain privacy provisions that differ from these policies. To ensure that your privacy is protected, we recommend that you review the privacy policies of other internet sites you visit.


Estimated Time:

Categories: Disaster, Infection, Pharmacology,
Content Type: External Resource,